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Abstract   
 
Context:  Salivary antibodies may act as non-invasive marker of systemic immunity 
enabling assessment of vaccination and protection against bacterial infections.  
Objective:  To assess if levels of anti-pneumococcal antibodies in saliva reflect 
concentrations in serum and determine whether saliva can accurately identify protective 
concentrations in serum.  
Methods:  IgG, IgA and IgM antibody levels in paired saliva and serum samples were 
measured against 12 pneumococcal polysaccharide antigens in 72 healthy adults.  
Results: Antibody levels in saliva correlated positively with serum across immunoglobulin 
classes, most strongly for IgA.  Individuals who had protective antibody levels in serum 
demonstrated significantly higher IgG and IgA salivary antibody concentrations/ secretion 
rates. Salivary IgG and IgA pneumococcal antibodies were able to distinguish between 
those with/ without protective levels in serum for the majority of serotypes. Salivary IgM 
antibodies were not able to differentiate protective status.  Median IgG and IgA 
pneumococcal salivary parameters were able to identify individuals who had protective 
levels in serum on ≥ 8/12 serotypes with moderate accuracy: median IgA secretion rates 
provided the best sensitivity (73%) and specificity (71%).     
Conclusions: These findings suggest that IgG and IgA pneumococcal specific antibodies 
in saliva may be useful surrogate markers of antibody status in serum.  
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Introduction 
Bacterial infections are a major cause of mortality across the world and even in high 
income countries are one of the commonest causes of death.  Streptococcus pneumoniae 
(S pneumoniae) is a colonising bacterium of the upper respiratory tract capable of causing 
invasive disease, such as pneumonia.  S pneumoniae causes up to half of community 
acquired pneumonia (CAP) (Brown, 2012), one of the leading causes of death in older 
adults in the UK and USA (Stupka, et al., 2009, Trotter, et al., 2008).  Bacterial infections 
due to S pneumoniae are mainly preventable through vaccination programmes, both within 
vaccinated individuals and the unvaccinated population as result of herd immunity.  
Ideally, vaccination efficacy should be tested in a randomised, double-blind, placebo-
controlled trial where the number of infections specific to the vaccine pathogen are 
evaluated between treatment and placebo arms.  An example is the recent Community-
Acquired Pneumonia Immunization Trial in Adults (CAPITA) that assessed the 13-valent 
polysaccharide conjugate vaccine (PCV13) against preventing first episodes of vaccine-
type CAP (Bonten, et al., 2015).  This trial included nearly 85,000 adults with a 
surveillance period spanning 5 years: trials such as these are extensive and accordingly 
expensive and not always viable.  Consequently, serum antibody levels have become an 
accepted surrogate marker of vaccine efficacy and also a method of determining if an 
individual is protected against certain pathogens.  Pneumococcal serotype protective cut-
offs were derived from a trial involving the 7-valent conjugate vaccine in infants (Black, et 
al., 2000).  Protective efficacy of the vaccine was 97.3% and > 97% of infants achieved > 
0.15 µg/mL; from this a non-specific serotype threshold of 0.20 µg/mL was allocated 
(Balmer, et al., 2007, Jodar, et al., 2003).  Subsequently, the WHO (2005) proposed a 
threshold of 0.35 µg/mL through associating ELISA data with clinical efficacy against 
invasive disease.  
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There are a number of practical considerations for acquiring blood to assess specific 
antibodies in serum.  These may be most pertinent for children and in poor resource 
settings, where risk of bacterial infection is often highest (Flanagan, et al., 2010).  A non-
invasive method of assessing protection against bacterial disease and vaccination 
responses could be particularly beneficial in countries introducing new vaccination 
programmes/aiming to increase coverage.  Saliva is an attractive method of specimen 
collection, particularly for children and the elderly, field research, or where repeated 
measures are required.  Saliva requires small sample volumes and is not considered a 
class II biohazard (US Centre for Disease Control), further collection requires no specialist 
training or equipment and may be more cost-effective (Mittal, et al., 2011).   
In infants, the 7-valent pneumococcal polysaccharide CRM197 protein conjugate vaccine 
(7VPnC) has been shown to induce salivary IgG and IgA antibody responses, but only 
following a booster vaccination (Choo, et al., 2000, Nurkka, et al., 2001).  In addition, 
infants vaccinated with 7VPnC still had significantly higher IgG and IgA pneumococcal 
salivary antibodies at 20–22 months post-vaccination compared with unvaccinated 
controls (Rodenburg, et al., 2012).  In these studies, IgG pneumococcal antibodies in 
saliva correlated with antibody levels in serum (Choo, et al., 2000, Nurkka, et al., 2001, 
Rodenburg, et al., 2012).  These findings in infants suggest vaccination may confer anti-
bacterial antibodies in saliva and that salivary antibodies may correlate well with systemic 
levels.  However, few studies have investigated salivary antibodies in adults.  
Saliva testing for specific antibodies has been advocated as a potential method of 
assessing systemic immunity and to monitor vaccination (Chiappin, et al., 2007, 
Rodenburg, et al., 2012), although the utility of saliva for these purposes has yet to be 
determined.  In addition, when multiple vaccine strains are assessed, such as in the case 
of pneumococcal vaccine, certain serotypes may be indicative of overall levels of 
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protection thus removing the need to assess all analytes.  The aims of the present study 
were to: assess to what extent levels of pneumococcal antibodies in saliva reflect 
concentrations in serum; determine whether antibody levels in saliva can accurately 
identify protective concentrations in serum; evaluate the relationship between different 
pneumococcal antibody serotypes in both saliva and serum.  
Materials and methods  
Participants  
Participants were 72 adults (34 females), aged 21–80 (median 51 years, SD ± 21 years) 
from Birmingham, UK.  All participants gave written informed consent prior to the study, 
which had the appropriate Ethics Committee approval.  All participants reported having 
good overall health, including oral health with no known teeth or gum problems.  None 
suffered from any acute illness in the two weeks prior to, or during the study.  
Serum and saliva collection   
Participants were asked to refrain from exercise and alcohol 24 h prior, and food and 
caffeine 12 h prior to arriving at the laboratory between 7–9am.  A 6mL venous blood 
sample was collected from an ante-cubital vein and an unstimulated whole-saliva sample 
was collected over 4 min into tubes weighed pre- and post-collection to determine saliva 
volume.  Samples were centrifuged and the separated serum and saliva supernatant were 
stored at –20°C until assay.  
Salivary and serum antibody measurements  
Saliva and serum were analysed using a multi-plex assay (Luminex-200, Bio-plex 
systems, BioRad Laboratories, California, USA) that simultaneously measured antibody 
concentrations against 12 pneumococcal (Pn) antigens (serotypes 1, 3, 4, 5, 6B, 7F, 9V, 
14, 18C, 19A, 19F, 23F).  This assay has been described in detail previously (Heaney, et 
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al., 2015, Whitelegg, et al., 2012).  Serum and saliva samples were assayed three times 
each to measure IgG, IgM and IgA antibody classes.   
Data Analysis  
For saliva, the following parameters were assessed: antibody concentrations, salivary flow 
rate (volume/collection time) and antibody secretion rate (flow rate x antibody 
concentration).  Saliva secretion rates are reported to reflect the availability of 
immunoglobulin at the oral surface and to control for hydration status (Oliver, et al., 2007).   
As data were not normally distributed, Spearman’s rank correlation was used to assess 
relationships between salivary antibody concentrations/secretion rates and serum antibody 
concentrations for each serotype for IgG, IgA and IgM, respectively.  Correlation 
coefficients were classed as weak (.1–.39), moderate (.4–.6) or strong (≥.6).  To examine if 
salivary IgA could be used as a proxy marker for IgG in serum - the dominant antibody 
classes in each of the specimens - the relationship between IgG serum and IgA saliva Pn 
antibodies were directly assessed.  Correlations were also used to evaluate relationships 
between Pn serotypes within serum and saliva.  
For IgG protective levels in serum, the following cut-offs were applied: Pn antibody 
serotypes, 0.35 μg/mL for protection (WHO, 2005) (minimum protective level) and 1.3 
μg/mL for the prevention of colonization and infection (Bonilla, et al., 2005) (optimal 
protective level).  Mann Whitney U tests were used to compare saliva IgG, IgM and IgA 
antibody concentration and secretion rates between individuals who did/did not exhibit 
protective levels in serum for Pn serotypes (≥ 0.35 μg/mL vs < 0.35 μg/mL).  
Receiver operating characteristic (ROC) curves where generated to assess if salivary 
antibody levels can identify protective levels in serum.  When significant results were 
observed, accuracy was classified using area under the curve (AUC) with the following 
values: > .7 (moderate), .8–9 (good) or > .9 (excellent).  Salivary antibody concentration 
7 
 
and secretion rates of IgG, IgM and IgA antibodies specific for Pn serotypes were explored 
in relation to minimum protective levels in serum (≥ 0.35 μg/mL).  Composite saliva 
parameters were then created to provide an overall representation of Pn antibody levels in 
saliva: median concentration and median secretion rates for all Pn serotypes combined.  
These composite measures were examined in relation to protective status, classified as 
minimum protective levels (≥ 0.35 μg/mL) in serum for ≥ 8/12 Pn serotypes, using ROC 
curves.  This serum variable, protection for 2/3rds of serotypes, was selected as it 
represents a normal adult response to the 23-valent polysaccharide pneumococcal 
vaccine (PPV23; Pneumovax® 23).  The ability of composite saliva measures to identify 
optimal protective levels (≥ 1.30 μg/mL) was also assessed using ROC curves.  For ROC 
analyses in relation to composite saliva parameters, the best salivary cut-offs to 
discriminate between protective status in serum were identified using the points on curve 
closest to the (0, 1); distance was calculated for each observed cut-off point from the curve 
(distance = √[(1 – sensitivity)2 + (1 – specificity)2] and the point where the distance was 
minimum was selected.  All analyses were conducted using IBM SPSS statistics version 
21.  
 
Results  
Relationship between serum and saliva  
Figure 1 illustrates the relationship between IgG, IgM and IgA anti-Pn antibodies in serum 
and saliva.  In general higher antibody concentrations in serum were associated with 
higher concentrations in saliva; however, variability existed between serotypes and 
immunoglobulin classes.  Table 1 displays each specific correlation coefficient: the 
strongest relationships were observed for IgA antibodies.  Similar positive associations 
emerged for saliva concentration and secretion rates, where the majority were moderate 
and statistically significant.  When examining serum IgG antibodies in relation to saliva IgA 
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concentration and secretion rates, significant correlations emerged for most serotypes for 
both saliva parameters, although these were mainly weak-moderate with coefficients <.5  
(Table 2).  
[Figure 1 and Tables 1 and 2 here] 
Saliva concentration and secretion rates in relation to protective levels in serum  
A total of 70.8% of participants had IgG serotype specific levels of ≥ 0.35 μg/mL for ≥ 8/12 
Pn serotypes.  Only 18.1% of participants achieved levels of ≥ 1.3μg/mL on ≥ 8/12 Pn 
serotypes; however, 41.7% achieved this level for ≥ 6/12 serotypes.  Individuals with 
protective concentrations in serum had higher salivary secretion rates compared to those 
without, significantly so for 9/12 IgG, 1/12 IgM and 8/12 IgA antibody serotypes (Table 3).  
No statistics could be performed for Pn19A as all participants displayed protective levels.  
Similar outcomes were observed for saliva concentration: higher antibody levels were 
observed for protected individuals for 9/12 IgG and 8/12 IgA antibody serotypes (same 
serotypes as Table 3, except Pn4 was significant rather than Pn18C); no significant 
differences were found in IgM saliva concentration.  
[Table 3 here] 
 
ROC curve analyses to identify if salivary antibody levels can identify protection in 
serum 
The ability of Pn salivary antibodies to distinguish between those with and without 
minimum protective levels (≥ 0.35 μg/mL) in serum for each serotype is shown in Table 4.  
Salivary IgG antibodies were most effective in identifying those with protective levels and 
significant results were found for 9 serotypes, for both concentration and secretion rates; 
secretion rates generally returned slightly higher AUC values compared with 
concentrations.  Averaged across serotypes, AUC values were equivalent to a 78% 
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probability that individuals with protective levels in serum would have higher salivary 
antibody levels compared to those without protective levels, for both concentration and 
secretion rate. The most successful serotype for distinguishing protective status based 
upon saliva parameters was Pn7F, followed by Pn18C, Pn19F then Pn23F; AUCs were > 
.8 and subsequently classified as displaying good accuracy.  
Salivary IgA antibodies also indicated a level of accuracy in distinguishing protective status 
in serum.  Secretion rates generally returned slightly higher AUC values compared to 
concentration and values were significant for 8 and 7 serotypes for secretion rates and 
concentration, respectively.  Averaged across serotypes, the AUC values were equivalent 
to a 68% (IgA concentration) and 70% (IgA secretion rate) probability that individuals with 
protective levels in serum would have higher salivary antibody levels compared to those 
without protective levels.  Similar to IgG, the best serotypes for distinguishing protective 
status based upon saliva parameters were Pn23F and Pn7F, both classed as moderately 
accurate (AUC > .7)  Salivary IgM antibodies were not informative based upon AUC values 
and were not able to discriminate between individuals with/without protective antibody 
levels in serum.  
[Table 4 here] 
ROC curve analyses to identify if salivary antibody levels can identify protection in 
serum: composite saliva parameters  
The previous analyses of individual pneumococcal serotypes showed IgG and IgA were 
the most promising antibody classes; these were taken forward to explore composite 
saliva parameters for identifying protective status in serum.  Median salivary IgG and IgA 
concentration and secretion rates across Pn serotypes all together were calculated for 
each participant.  These composite measures were firstly examined in relation to minimum 
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protective levels (≥ 0.35 μg/mL) in serum for ≥ 8/12 Pn serotypes and corresponding ROC 
curves are shown in Figure 2.   
Median IgG concentration and secretion rates returned significant AUC values of .69 and 
.67, respectively.  The best-cut off for concentration was ≥ 0.69 ng/mL giving 76% 
sensitivity 76% and 62% specificity.  The best-cut off for secretion rate was ≥ 0.29 ng/min 
with sensitivity 65% and specificity 71%.  For IgA, median Pn antibody concentration 
generated an AUC of .67 with ≥ 8.54 ng/mL providing the best-cut off: 65% sensitivity and 
62% specificity.  Median IgA secretion rate AUC was .68 and a cut-off of ≥ 3.00 ng/min 
provided the best combination of sensitivity and specificity with values of 73% and 71%, 
respectively.   
[Figure 2 here] 
 
As only a minority of individuals exhibited the higher protective threshold of 1.30 μg/mL for 
≥ 8/12 serotypes, a lower number of serotypes (≥ 6/12) was selected to evaluate the 
higher level of protection in serum in relation to composite saliva parameters (Figure 3).   
Median IgG Pn concentration and secretion rates produced significant AUCs of moderate 
accuracy for identifying the higher level of protection in serum: AUC .71 and .73, 
respectively.  The best cut-offs were 1.10 ng/mL for concentration (67% sensitivity and 
69% specificity) and 0.51 ng/min for secretion rate (57% sensitivity and 81% specificity).  
Median IgA concentration resulted in an AUC of .66 and the best cut-off occurred at ≥ 
74.32 ng/mL with 70% sensitivity and 64% specificity. Median IgA secretion rate AUC was 
.66 and a ≥ 5.20 ng/min cut-off returned 57% sensitivity and 76% specificity.  
[Figure 3 here] 
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Relationships between pneumococcal serotypes  
The relationships between serotypes for IgG in serum are shown in Supplementary Table 
1.  Pn9V was most representative of the other serotype specific antibody concentrations, 
which was significantly positively associated with 9 serotypes.  The best average 
coefficients across serotypes were observed for Pn7F and Pn9V and Pn19F.  Stronger 
associations were observed for saliva than serum. The majority of correlations were 
significant and moderate-strong for IgG secretion rates (Supplementary Table 2). The best 
average correlation coefficients were observed for Pn9V and Pn19A followed by Pn4 and 
Pn5.  For IgG concentration, inter-serotype correlations were generally significant but not 
as strong as secretion rates, again 9V and 19A had the strongest correlation coefficients.  
For IgA secretion rates, all inter-serotype correlations were significant and the majority 
were strong: Pn9V had the strongest average coefficient, followed by Pn19F and Pn3 
(Supplementary Table 3). For IgA saliva concentration, correlations were not as robust as 
secretion rates, although 8 serotypes correlated significantly with all 11 other serotypes.  
Serotype Pn9V was followed-up to determine if a single candidate was able to act as a 
measure of overall antibody pneumococcal levels within each biological specimen.  Using 
ROC curve analyses, Pn9V concentration was tested against protective status in serum.  
Concentration of Pn9V in serum was able to identify participants with protective levels for ≥ 
8/12 serotypes from those who did not with a good level of accuracy: AUC = .86 (95% CI 
.74–.97, p < .001). The best cut-off (378.9 ng/mL) provided 92% sensitivity and 81% 
specificity.  To assess if Pn9V was related to overall antibody levels within saliva ‘higher’ 
and ‘lower’ median Pn groups were created using median splits of antibody secretion 
rates.  ROC curves were then generated to test the ability of Pn9V secretion rates in saliva 
to discriminate between higher and lower overall Pn antibody groups.  For IgG, Pn9V 
secretion rates distinguished between those with higher overall Pn antibody secretion from 
those with lower levels: AUC = .93 (95% CI .88–.98, p < .001). The best cut-off secretion 
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rate at 0.25 ng/min gave 88% sensitivity and 84% specificity.  IgA Pn9V secretion rates 
were also able to successfully identify higher/lower overall Pn antibody secretion.  A 
significant AUC of .92 was observed (95% CI .86–.99, p < .001) and the best cut-off 
occurred at 3.63 ng/min with 89% sensitivity and 92% specificity.  
 
Discussion  
Salivary concentration and secretion rates positively correlated with serum antibodies 
within immunoglobulin class; these findings indicate anti-pneumococcal antibody levels in 
serum are broadly reflected by those in saliva.  This is consistent with previous studies 
showing positive associations between salivary and serum anti-pneumococcal antibodies 
in infants (Choo, et al., 2000, Nurkka, et al., 2001, Nurkka, et al., 2004, Rodenburg, et al., 
2012) and the present study extends these findings to adults.  Interestingly, the strongest 
relationships between serum and saliva were observed for IgA antibodies, rather than IgG 
where salivary antibodies are considered to be mainly serum-derived (Kauppi, et al., 1995, 
Nurkka, et al., 2001).  Most IgA in saliva is secreted by local plasma cells and synthesised 
in dimeric form; pentameric IgM is also secreted locally (Brandtzaeg, 2007).  Alternatively, 
IgG and the majority of monomeric IgA present in saliva is derived from serum rather than 
local production; these are likely to enter the saliva through gingival crevices, via gingival 
crevicular fluid (Brandtzaeg, 2007, Hofman, 2001).  Although correlations between IgG in 
serum and IgA in saliva were not convincing, salivary IgA antibodies were linked to 
protective status in serum.  When examining individual anti-serotype antibodies, a level of 
≥ 0.35 μg/mL in serum was associated with significantly higher IgG and IgA antibody 
concentrations and secretion rates in saliva, although not IgM.  Overall, the present results 
demonstrate that protective levels in serum are linked to higher levels of antibodies in 
saliva.  Salivary immunoglobulins have been proposed to comprise a broad defence 
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system capable of inhibiting bacterial adherence and thus colonisation (Van Nieuw 
Amerongen, et al., 2004).  Stimulation of salivary antibodies may be advantageous as 
most bacterial pathogens enter the body via mucosal routes (Flanagan, et al., 2010). The 
higher salivary antibodies observed parallel to serum may offer enhanced protection 
against pneumococcal infection.  Although the importance of mucosal antibodies as a 
defence mechanism requires further investigation (Nurkka, et al., 2005).  
We tried to determine whether saliva parameters are representative of distinct antibody 
cut-offs in serum deemed to be indicative of protective status (Bonilla, et al., 2005; WHO, 
2005).  When analysing individual antibodies paired in serum and saliva for pneumococcal 
serotypes, salivary IgG antibodies were most effective in identifying those with protective 
levels in serum.  This is perhaps to be expected given protective status in serum is based 
upon IgG. Both concentrations and secretion rates were able to distinguish protective 
status in serum with moderate accuracy. On average there was > 70% chance that an 
individual with protective antibody levels in serum would have higher salivary antibodies 
compared with an unprotected individual.  Although AUCs were on average not as high as 
IgG, salivary IgA antibodies also indicated a degree of accuracy in differentiating protective 
status in serum for several serotypes.  For both IgG and IgA, Pn7F and Pn23F were the 
most sensitive in identifying protective status.  
For paired serum and saliva analysis, IgG and IgA salivary antibodies were largely fair to 
good indicators of protective status in serum.  The observed AUC values can be 
interpreted as adequate/acceptable discrimination between protection groups.  However, 
saliva was not useful in identifying protective status in all serotypes.  Further, the analyses 
of individual serotypes may not be feasible or appropriate in population studies, where a 
global indicator of protection from pneumococcal disease or response to vaccination is 
likely to be of added interest.  Composite saliva measures were explored to examine the 
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sensitivity and specificity from identified best-cut off points.  This strategy provided an 
antibody profile across pneumococcal serotypes to be tested against overall protective 
status in serum, which due to ease of calculation could be easily applied in large 
investigations.  Identifying protective status in relation to 2/3rds of serotypes by composite 
saliva parameters approached moderate accuracy.  The best balance between sensitivity 
and specificity was observed for median IgA secretion rates, with values of 73% and 71% 
associated with the best cut-off.  A cut-off of ≥ 3.00 ng/min successfully identified the 
majority of individuals who met the WHO criteria for protection on ≥ 8/12 serotypes in this 
sample population, however, a false positive/negative rate of nearly 30% still existed.  The 
strongest AUCs for composite measures were seen for IgG concentration and secretion for 
identifying the higher threshold for protection for ≥ 6/12 serotypes.  Although a range of 
sensitivity and specificity values were observed for both IgG and IgA salivary cut-offs in 
relation to distinguishing the higher level of protection.   
Depending on the purpose of the test and impact of the results, the importance of 
sensitivity and specificity may fluctuate with the consequences of false positives/false 
negatives.  If using a saliva-based test to inform clinical decisions at an individual-level a 
higher level of performance would need to be developed than what was observed in the 
present study.  However, these preliminary results suggest that measuring pneumococcal 
specific antibodies in saliva may have promise in future epidemiological studies relating to 
vaccination and protection from pneumococcal disease.  The cut-offs identified in this 
study were specific for the population investigated and our multiplex assay; larger 
population studies would need to be performed to establish cut-offs in saliva indicative of 
specific levels in serum.  The use of the WHO protective cut-off was employed in this study 
as a means of assessing if saliva can identify specific serum thresholds.  However, it is 
acknowledged that 0.35 μg/mL is an estimation (Nurkka, et al., 2005)  and true protective 
levels may vary for the different serotypes and in relation to age.  Pneumococcal conjugate 
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vaccines have been shown to induce salivary antibodies in infants (Nurkka, et al., 2004, 
Nurkka, et al., 2005, Rodenburg, et al., 2012).  No vaccinations were administered as part 
of this cross-sectional study examining salivary antibodies in relation to serum in adults.  In 
order to assess if salivary antibodies can act as a marker of vaccination, the utility of saliva 
needs to be tracked over time in response to vaccination in different age groups of 
interest, including children and elderly adults. 
If certain serotypes provide good estimation of overall protection against pneumococcal 
disease then they could be used as a cost and resource effective proxy marker when 
measuring a range of serotypes is not possible.  Selecting key serotypes as universal 
representatives of antibody levels across serotypes could also help streamline studies and 
aid interpretation and analysis when investigating multiple analytes.  Inter-serotype 
relationships were stronger within saliva than in serum, with IgA secretion rates showing 
the strongest correlations.  Serotype Pn9V gave the strongest correlations in both serum 
and saliva and was explored further as an indicator of overall antibody status.  IgG and IgA 
Pn9V secretion rates were able to identify participants with higher median Pn antibody 
secretion rates with a high degree of accuracy.  Therefore, this serotype may provide a 
good indication of pneumococcal antibodies in saliva.  In serum, Pn9V was able to 
correctly distinguish between protection statuses: levels were highly sensitive and specific 
in identifying those with protection for 2/3rds of serotypes in serum in this sample. 
Serotype Pn9V is present in both Pneumovax and Prevnar 13, and thus could be a useful 
indicator of overall response to these vaccinations. However, this should perhaps be 
interpreted with some caution. As mentioned previously, in reality precise protective levels 
could vary between serotypes. 
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Conclusions  
This study provides initial evidence that antibodies against pneumococcal antigens in 
serum are broadly reflected by saliva across immunoglobulin classes, IgA, IgG and IgM.  
Individuals who had protective levels of anti-pneumococcal antibodies in serum 
demonstrated significantly higher IgG and IgA salivary antibody concentrations and 
secretion rates. Salivary IgG and IgA antibodies showed reasonable accuracy in 
distinguishing protective status in serum; it was not possible to identify protective levels 
using IgM. Levels of certain pneumococcal serotypes are interrelated and Pn9V may be a 
potential candidate to represent overall pneumococcal antibody status.  Saliva sampling 
may be able to help address the challenges of measuring antibodies in certain populations 
and settings and offer a potential biomarker of systemic immunity and vaccination; future 
studies in large populations are required to develop, optimise and validate further.  
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Table 1. Spearman’s rank correlation coefficients (rs) for each pneumococcal (Pn) 
serotype within immunoglobulin class.  Correlations are between serum IgG, IgM and IgA 
concentrations, respectively, and saliva concentration and saliva secretion rates for IgG, 
IgM and IgA, respectively; *** p < .001, ** p < .01, * p < .05  
 
 Saliva concentration Saliva secretion rate 
rs 
 
IgG IgM IgA IgG IgM  IgA  
Pn1 .35** .31* .56*** .38** .39** .53*** 
Pn3 .53*** .55*** .57*** .47*** .53*** .56*** 
Pn4 .26* .34** .52*** .30* .34** .55** 
Pn5 .42** .47*** .67*** .52*** .49*** .68*** 
Pn6B .48*** .23 .42*** .52*** .24 .42*** 
Pn7F .34** .32** .49*** .34** .42*** .49*** 
Pn9V .55*** .15 .58*** .52*** .20 .54*** 
Pn14 .29* .36** .43*** .29* .14 .48*** 
Pn18C .40** .64*** .56*** .69*** .39** .51*** 
Pn19A .48*** .25* .57*** .45*** .30* .44*** 
Pn19F .25* .47*** .22 .24* .51** .23* 
Pn23F .64*** .27* .64*** .61*** .34* .67*** 
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Table 2.  Spearman’s rank correlation coefficients (rs) for antibodies against 
pneumococcal (Pn) serotypes for IgG in serum and salivary IgA concentration and IgG in 
serum and salivary IgA secretion; *** p < .001, ** p < .01, * p < .05 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
rs 
 
Concentrations of 
IgG in serum and 
IgA in saliva 
Concentration  of IgG in 
serum and IgA secretion 
rate in saliva  
Pn1 .30* .33** 
Pn3 .44** .47*** 
Pn4 .37** .38** 
Pn5 .12 .24* 
Pn6B .29* .30* 
Pn7F .37** .34** 
Pn9V .32** .30* 
Pn14 .47** .35** 
Pn18C .26* .31* 
Pn19A .28* .29* 
Pn19F .15 -.01 
Pn23F .48** .46*** 
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Table 3.  Salivary IgG, IgM and IgA antibody secretion rates specific for pneumococcal (Pn) serotypes (ng/min), for those who did/did not 
demonstrate minimum protective antibody levels in serum for each serotype, respectively.  All individuals had protective titres for Pn19A; 
*** p < .001, ** p < .01, * p < .05 
 
 
 
 IgG IgM  IgA 
 Protected  Not protected  Protected  Not protected  Protected  Not protected  
Pn1 .55 (.08–5.65)** .24 (.02–.04) 1.30 (0.3–10.45) .93 (.01–8.09) 1.82 (0.16–16.54)** 1.0 (.11–10.04) 
Pn3 .13 (.02–1.49)** .06 (.01–.63) .20 (.02–1.76) .12 (0–5.33) 16.72 (2.08–261.16)*** 10.56 (1.01–65.47) 
Pn4 .12 (.01–1.75) .09 (0–.96) .47 (.01–4.68) .41 (.01–4.38) 4.14 (.72–138.67) 3.78 (.29–31.07) 
Pn5 .44 (.07–71.55)** .23 (.01–.38) 1.71 (.04–16.98) .55 (.14–9.59) 1.36 (.12–7.53) .98 (.10–6.03) 
Pn6B .26 (.03–56.64)** .10 (.01–3.35) 4.61 (.12–26.77)* 2.44 (.13–22.45) 6.56 (.23–31.31)* 2.0 (.33–14.43) 
Pn7F .89 (.02–11.16)** .12 (.03–.63) .68 (.03–18.26) .46 (.10–1.70) 2.51 (.12–20.94)* .80 (.18–3.14) 
Pn9V .34 (.02–3.78)** .10 (.01–1.39) 1.10 (.04–11.25) .71 (.06–6.31) 5.03 (.15–31.79)* 1.98 (.20–31.72) 
Pn14 .50 (.02–47.19) .17 (0.1–13.24) .34 (0–35.49) .17 (0–14.79) 9.35 (1.10–420.24)* 3.77 (.87–27.43) 
Pn18C .24 (.02–51.06)*** .05 (0–.17) .48 (0.1–6.02) .33 (.09–1.56) 2.14 (.12–38.48)* .57 (.11–4.91) 
Pn19A 2.18 (.11–21.21) – 1.34 (.06–3.61) – 8.65 (1.17–58.91)  – 
Pn19F 1.96 (.08–31.31.37)** .37 (0.6–1.72) 5.19 (.09–91.17) 1.64 (.30–15.51) 10.42 (.97–85.33) 6.10 (2.61–10.27) 
Pn23F .28 (.02–22.15)*** .07 (0–.82) 2.14 (.13–18.86) 1.8 (.08–16.63) 3.74 (.24–19.39)*** 1.05 (.21–18.41) 
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Table 4. Area under curve (AUC (95% confidence intervals)) results for receiver operating characteristic (ROC) curves for saliva IgG, IgM 
and IgA concentrations and secretion rates to identify protective IgG antibody levels in serum (≥ 0.35 μg/mL) from those who did not 
have protective levels (< 0.35 μg/mL) for each pneumococcal (Pn) serotype.  All individuals had protective titres for Pn19A; *** p < .001, 
** p < .01, * p < .05 
 Saliva concentration  Saliva secretion rate  
AUC (95% CI) IgG IgM IgA  IgG IgM IgA  
Pn1 .70 (.58–.83)** 0.51 (.38–.65) .66 (.53–79)* .68 (.55–.80)* 0.58 (.45–.72) .68 (.56–.81)** 
Pn3 .77 (.66–.88)*** 0.55 (.42–.69) .70 (.58–.82)** .81 (.70–.91)*** 0.59 (.46–.73) .71 (.60–.83)** 
Pn4 .57 (.42–.71) 0.60 (.46–.74) .66 (.53–.79)* .59 (.45–.73) 0.59 (.45–.73) .59 (.46–.73) 
Pn5 .80 (.67–.92)** 0.60 (.42–.79) .59 (.41–.77) .79 (.64–.94)** 0.69 (.51–.88) .62 (.42–.81) 
Pn6B .73 (.62–.85)** 0.60 (.47–.74) .65 (.52–.77)* .70 (.58–.83)** 0.67 (.54–.80)* .67 (.55–.80)* 
Pn7F .90 (.80–1.00)** 0.54 (.32–.75) .74 (.57–.92)* .88 (.76–.99)** 0.62 (.42–.83) .77 (.62–.93)* 
Pn9V .76 (.63–.88)** 0.59 (.45–.73) .71 (.57–.85)** .80 (.65–.91)*** 0.62 (.47–.77) .68 (.54–.81)* 
Pn14 .62 (.46–.78) 0.57 (.40–.73) .67 (.53–.81)* .60 (.45–.76) 0.60 (.45–.75) .69 (.55–.82)* 
Pn18C .85 (.75–.96)*** 0.44 (.28–.59) .68 (.50–.86) .83 (.73–.94)** 0.52 (.37–.68) .75 (.59–.90)* 
Pn19F .85 (.70–1.00)** 0.55 (.31–.78) .63 (.36–.90) .84 (.70–.98)* 0.62 (.35–.88) .75 (.59–.91) 
Pn23F .84 (.75–.93)*** 0.47 (.33–.60) .78 (.67–.89)*** .85 (.76–.94)*** 0.53 (.39–.66) .76 (.64–.87)*** 
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Figure 1. IgG, IgM and IgA (from left to right) pneumococcal antibody levels in serum (x axis) and saliva (y axis) for 12 pneumococcal serotypes.  
Data illustrate overall positive correlations between serum and saliva and variability between serotypes  
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Figure 2. Receiver operating characteristic curves of salivary IgG (A) and salivary IgA (B) antibody 
parameters for identifying minimum protective antibody levels (≥ 0.35 μg/mL) in serum on ≥ 8/12 
pneumococcal serotypes.  Saliva measures are median antibody concentration and secretion rate 
overall for all pneumococcal serotypes combined.  
Panel A:  Median IgG concentration (solid line) AUC = .69 (95% CI .54–.84), p = .012; best cut-off 
0.69 ng/mL, sensitivity 76% and specificity 62 %. Median IgG secretion rate (dotted line) AUC = 
.67 (95% CI .54–.81), p = .022; best cut-off 0.29 ng/min, sensitivity 65% and specificity 71%.  
Panel B: Median IgA concentration (solid line) AUC = .67 (95% CI .52–.82), p = .022; best cut-off 
8.54 ng/mL, sensitivity 65% and specificity 62%. Median IgA secretion rate (dotted line) AUC = .68 
(95% CI .55–.81), p = .017; best cut-off 3.00 ng/min, sensitivity 73% and specificity 71%.  
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Figure 3. Receiver operating characteristic curves of salivary IgG (A) and salivary IgA (B) antibody 
parameters for identifying optimal protective antibody levels (≥ 1.30 μg/mL) in serum on ≥ 6/12 
pneumococcal serotypes.  Saliva measures are median antibody concentration and secretion rate 
overall for all pneumococcal serotypes combined.  
Panel A:  Median IgG concentration (solid line) AUC = .71 (95% CI .59–.83), p = .001; best cut-off 
1.10 ng/mL, sensitivity 67% and specificity 69 %. Median IgG secretion rate (dotted line) AUC = 
.73 (95% CI .61–.81), p = .002; best cut-off 0.51 ng/min, sensitivity 57% and specificity 81%.  
Panel B: Median IgA concentration (solid line) AUC = .66 (95% CI .53–.79), p = .025; best cut-off 
74.32 ng/mL, sensitivity 70% and specificity 64%. Median IgA secretion rate (dotted line) AUC = 
.67 (95% CI .54–.79), p = .013; best cut-off 5.20 ng/min, sensitivity 57% and specificity 76%.  
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Supplementary Table 1. Correlations between for pneummococcal (Pn) serotypes for IgG antibody levels in serum. Light gery shading indicates a 
moderate relationship between serotypes; ***p < .001, **p < .01, *p < .05 
rs Pn1 Pn3 Pn4 Pn5 Pn6B Pn7F Pn9V Pn14 Pn18C Pn19A Pn19F Pn23F 
Pn1 
 
.20 .13 .43*** .33** .15 .38** .23 .33* .13 .38** .30* 
Pn3 .20 
 
.10 .04 .23 .40** .31* -0.03 .19 .02 .27* -0.06 
Pn4 .13 .10 
 
.27* .30* .27* .16 .24* .08 .26* .35** .17 
Pn5 .43*** .04 .27* 
 
.29* .26* .33** .34** .22 .41** .25* .15 
Pn6B .33** .23 .30* .29* 
 
.22 .50*** .20 .18 .18 .19 .30* 
Pn7F .15 .40** .27* .26* .22 
 
.43*** .19 .23 .25* .52*** .23 
Pn9V .38** .31* .16 .33** .50*** .43*** 
 
.21 .28* .42*** .45*** .37** 
Pn14 .23 -.03 .24* .34** .20 .19 .21 
 
.35** .24* .17 .23 
Pn18C .33* .19 .08 .22 .18 .23 .28* .35** 
 
-.09 -.10 .29* 
Pn19A .13 .02 .26* .41** .18 .25* .42*** .24* -.09 
 
.49*** .21 
Pn19F .38** .27* .35** .25* .19 .52*** .45*** .17 -.10 .49*** 
 
.23 
Pn23F .30* -.06 .17 .15 .30* .23 .37** .23 .29* .21 .23 
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Supplementary Table 2.  Correlations between pneummococcal (Pn) serotypes for IgG antibody saliva secretion rates. Light gery shading indicates 
a moderate relationship and darker shading indicates a strong relationship between serotypes; p < .05 for all correlations except Pn18C vs Pn 3,14 
and 19F and Pn14  vs 6B  
 
 
 
 
 
 
 
 
 
 
 
rs Pn1 Pn3 Pn4 Pn5 Pn6B Pn7F Pn9V Pn14 Pn18C Pn19A Pn19F Pn23F 
Pn1 
 
.45 .62 .74 .69 .68 .80 .23 .49 .82 .62 .77 
Pn3 .45  .73 .38 .31 .51 .48 .60 .19 .48 .74 .45 
Pn4 .62 .73  .71 .50 .76 .70 .57 .33 .75 .84 .60 
Pn5 .74 .38 .71  .67 .82 .84 .32 .52 .82 .61 .72 
Pn6B .69 .31 .50 .68  .53 .72 .14 .55 .66 .43 .69 
Pn7F .68 .51 .76 .82 .53  .87 .29 .41 .85 .65 .64 
Pn9V .79 .48 .70 .84 .72 .87  .28 .53 .88 .67 .71 
Pn14 .23 .60 .57 .32 .14 .29 .28  .07 .32 .65 .30 
Pn18C .49 .19 .33 .52 .55 .41 .53 .07  .40 .18 .56 
Pn19A .82 .48 .75 .82 .66 .85 .88 .32 .40  .72 .74 
Pn19F .61 .74 .84 .61 .43 .65 .67 .65 .18 .72  .50 
Pn23F .77 .45 .60 .72 .69 .64 .71 .30 .56 .74 .50  
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Supplementary Table 3.  Correlations between pneummococcal (Pn) serotypes for IgA antibody saliva secretion rates. Light gery shading indicates 
a moderate relationship and darker shading indicates a strong relationship between serotypes; p < .001 for all correlations   
rs Pn1 Pn3 Pn4 Pn5 Pn6B Pn7F Pn9V Pn14 Pn18C Pn19A Pn19F Pn23F 
Pn1 
 
0.55 0.71 0.64 0.55 0.56 0.60 0.56 0.57 0.48 0.57 0.56 
Pn3 0.55  0.69 0.67 0.56 0.66 0.70 0.70 0.56 0.61 0.67 0.57 
Pn4 0.71 0.69  0.59 0.54 0.63 0.67 0.65 0.56 0.55 0.71 0.53 
Pn5 0.64 0.67 0.59  0.67 0.57 0.64 0.58 0.66 0.64 0.63 0.57 
Pn6B 0.55 0.56 0.54 0.67  0.61 0.68 0.49 0.76 0.67 0.57 0.66 
Pn7F 0.56 0.66 0.63 0.57 0.61  0.74 0.63 0.65 0.64 0.65 0.49 
Pn9V 0.60 0.70 0.67 0.64 0.68 0.74  0.58 0.63 0.70 0.61 0.53 
Pn14 0.56 0.70 0.65 0.58 0.49 0.63 0.58  0.54 0.62 0.79 0.53 
Pn18C 0.57 0.56 0.56 0.66 0.76 0.65 0.63 0.54  0.59 0.50 0.69 
Pn19A 0.48 0.61 0.55 0.64 0.67 0.64 0.70 0.62 0.59  0.67 0.53 
Pn19F 0.57 0.67 0.71 0.63 0.57 0.65 0.61 0.79 0.50 0.67  0.53 
Pn23F 0.56 0.57 0.53 0.57 0.66 0.49 0.53 0.53 0.69 0.53 0.53  
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